Novanta stock just jumped 6.7% in a single session, and that move highlights how emotionally charged this earnings season has become. The market responded to a clear headline of double digit revenue growth in Q2 and an increase to full year guidance.
Beneath the excitement, the key drivers were margins and cash. Adjusted gross margin reached 47% and adjusted earnings per share rose at a double digit rate, while free cash flow for the quarter was about US$65 million. For a high multiple medical and industrial technology stock, that combination is what moved the needle today.
Love Novanta's margin strength and cash generation but want a broader set of high quality compounders to compare it with? Check out our screener of list of solid balance sheet and fundamentals stocks (49 results).
Q2 2026 Earnings Summary
- Revenue, Q2 2026 vs. Q2 2025: US$265.8 million vs. US$241.0 million (up 10.3%)
- Net Income, Q2 2026 vs. Q2 2025: US$12.5 million vs. US$4.5 million (up 178.7%)
- Basic EPS, Q2 2026 vs. Q2 2025: US$0.31 vs. US$0.12 (up 144.9%)
- Adjusted Gross Margin, Q2 2026 vs. Q2 2025: 47.0% vs. 46.0% (up 1.0 percentage point)
Prefer clear visuals instead of another wall of earnings tables and ratio breakdowns? See Novanta's full financial picture with an easy read on its valuation, cash generation profile and recent results in the company report for Novanta..
Novanta bull case: margins, mix and cash in focus
Bulls argue Novanta is turning secular robotics and medical device demand into higher quality growth with better margins and more recurring revenue. Q2 gives some support. Revenue grew 10% with 9% organic, adjusted gross margin reached 47%, and adjusted EBITDA rose 16% while adjusted EPS increased 17%. Automation Enabling Technologies margins moved to about 53%, helped by higher margin products and duty recovery, which is what the margin story needs. Free cash flow of US$65 million in the quarter and US$117 million year to date, already above all of 2025, backs the cash generation angle. Closing Riverpoint and raising 2026 guidance, including higher EBITDA and EPS ranges, also fits the narrative of more medical and consumables exposure. The main soft spot is Medical Solutions margin at about 41%, which is below last year and shows the medical mix is not yet translating into cleaner profitability.
Novanta bear case: acquisition risk and execution stress test
Bears worry that Novanta relies on acquisitions and restructuring, with patchy organic growth and pressured margins, and that this leaves little room for error. Q2 does not fully support that view, but it does not remove it either. Organic growth of 9% and a 1.1 book to bill in Automation Enabling Technologies challenge the idea of a weak core. However, Medical Solutions book to bill of 0.79 in the quarter and lower segment margin show uneven demand and profit quality. The Riverpoint deal lifts medical exposure to roughly 60% of revenue and recurring consumables to about US$300 million, but it also pushes pro forma gross debt to just above US$800 million, with leverage near 2.7x. Equity issuance of roughly US$300 million confirms some dependence on capital markets. Site closures and transformation charges inside Medical Solutions also keep execution risk firmly on the table.
Review Novanta's restructuring exposure and acquisition driven growth, then scan the full risk analysis for Novanta which shows 1 important warning signStay Ahead With Simply Wall St
Novanta's mix of margin performance, cash generation and acquisition activity can make timing and risk assessment tricky, so register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for your preferred entry point. After you own Novanta or other stocks, use the Portfolio Command Center to cut through market noise and focus on the updates that actually matter to your holdings. For longer term decisions, tap into the crowd insights inside the Community and see how other investors are thinking about similar risks and opportunities. By surfacing potential catalysts and warning signs early, Simply Wall St helps you act with confidence and stay a step ahead of the market.
Seeking Alternatives Beyond Novanta Stock
Fresh ideas can move before the headlines catch up. Spot potential breakouts while momentum is building, not after prices are moving sharply. These curated shortlists aim to be useful before the crowd focuses on them, so consider reviewing them early.
- Explore potential opportunities in steadier operators and stress test your current picks against a curated 77 resilient stocks with low risk scores while the entries may still be less widely followed.
- Follow developing themes in automation and AI hardware by scanning a hand picked pool of 56 AI infrastructure stocks before the trends become more broadly recognized.
- Look for possible growth stories in robotics, logistics and factory upgrades by focusing on carefully filtered 36 robotics and automation stocks while valuations may still appeal to investors taking an early interest.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com